Overview

Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech companies and fostering a culture of innovation that allows us to maintain our leadership position in the space. • Best-in-class LNP + next generation ligand conjugate technologies • First and only FDA-approved siRNA-LNP utilizes Genevant technology • Nucleic acid payload design expertise • Several hundred patents worldwide • LNP technology evaluated in more than a dozen clinical programs, representing hundreds of subjects and patients • An established leader in delivery to the liver, now focusing capabilities on other tissues and cell types • Experienced team with deep technical expertise and a track record of innovation and creative corporate partnering